SG11202101853PA - Humanized anti-c5 antibodies and uses thereof - Google Patents

Humanized anti-c5 antibodies and uses thereof

Info

Publication number
SG11202101853PA
SG11202101853PA SG11202101853PA SG11202101853PA SG11202101853PA SG 11202101853P A SG11202101853P A SG 11202101853PA SG 11202101853P A SG11202101853P A SG 11202101853PA SG 11202101853P A SG11202101853P A SG 11202101853PA SG 11202101853P A SG11202101853P A SG 11202101853PA
Authority
SG
Singapore
Prior art keywords
antibodies
humanized anti
humanized
Prior art date
Application number
SG11202101853PA
Inventor
Wenchao Song
Takashi Miwa
Damodar Gullipalli
Ping Tsui
Sayaka Sato
Original Assignee
Univ Pennsylvania
Kira Pharmaceuticals Us Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania, Kira Pharmaceuticals Us Llc filed Critical Univ Pennsylvania
Publication of SG11202101853PA publication Critical patent/SG11202101853PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0393—Animal model comprising a reporter system for screening tests
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8527—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic for producing animal models, e.g. for tests or diseases
    • C12N2015/859—Animal models comprising reporter system for screening tests

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202101853PA 2018-09-06 2019-09-06 Humanized anti-c5 antibodies and uses thereof SG11202101853PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862727666P 2018-09-06 2018-09-06
US201962837833P 2019-04-24 2019-04-24
PCT/US2019/049890 WO2020051418A1 (en) 2018-09-06 2019-09-06 Humanized anti-c5 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
SG11202101853PA true SG11202101853PA (en) 2021-03-30

Family

ID=69723287

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202101853PA SG11202101853PA (en) 2018-09-06 2019-09-06 Humanized anti-c5 antibodies and uses thereof

Country Status (12)

Country Link
US (1) US20220177556A1 (en)
EP (1) EP3846850A4 (en)
JP (1) JP2021536509A (en)
KR (1) KR20210055742A (en)
CN (1) CN113038967A (en)
AU (1) AU2019336214A1 (en)
BR (1) BR112021004141A2 (en)
CA (1) CA3111396A1 (en)
IL (1) IL281272A (en)
MX (1) MX2021002710A (en)
SG (1) SG11202101853PA (en)
WO (1) WO2020051418A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019018429A2 (en) * 2017-03-06 2020-04-14 Univ Pennsylvania antibody, methods for treating an individual's complement-mediated disease or disorder and for reducing the activity of an individual's complement system, and, cell
CN114072174A (en) * 2019-04-24 2022-02-18 宾夕法尼亚大学理事会 Dual-function humanized anti-C5 antibody and factor H fusion protein and uses thereof
CN113563467A (en) * 2020-04-28 2021-10-29 上海普铭生物科技有限公司 Antibodies against human complement protein C5 and uses thereof
CN114149501B (en) * 2020-12-11 2023-05-26 天士力生物医药股份有限公司 anti-C5 antibodies and uses thereof
WO2023050233A1 (en) * 2021-09-29 2023-04-06 The Trustees Of The University Of Pennsylvania Humanized anti-c5a antibodies and uses thereof
WO2024097796A1 (en) 2022-11-02 2024-05-10 Kira Pharmaceuticals (Us) Llc Anti-c5 antibody fused to factor h for use in the treatment of complement-mediated diseases
WO2024097441A1 (en) 2022-11-02 2024-05-10 Kira Pharmaceuticals (Us) Llc Anti-c5 antibody fused to factor h for use in the treatment of complement-mediated diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8410251B2 (en) * 2008-06-20 2013-04-02 National University Corporation Okayama University Antibody against calcified globule and use of the same
US20160051673A1 (en) * 2013-03-29 2016-02-25 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
NZ631007A (en) * 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
PL3233921T3 (en) * 2014-12-19 2022-01-10 Chugai Seiyaku Kabushiki Kaisha Anti-c5 antibodies and methods of use
EP3472316A4 (en) * 2016-06-17 2020-01-08 Chugai Seiyaku Kabushiki Kaisha Anti-c5 antibodies and methods of use
BR112019018429A2 (en) * 2017-03-06 2020-04-14 Univ Pennsylvania antibody, methods for treating an individual's complement-mediated disease or disorder and for reducing the activity of an individual's complement system, and, cell
CN114072174A (en) * 2019-04-24 2022-02-18 宾夕法尼亚大学理事会 Dual-function humanized anti-C5 antibody and factor H fusion protein and uses thereof

Also Published As

Publication number Publication date
CN113038967A (en) 2021-06-25
EP3846850A4 (en) 2022-06-15
KR20210055742A (en) 2021-05-17
CA3111396A1 (en) 2020-03-12
US20220177556A1 (en) 2022-06-09
MX2021002710A (en) 2021-09-23
WO2020051418A1 (en) 2020-03-12
JP2021536509A (en) 2021-12-27
IL281272A (en) 2021-04-29
EP3846850A1 (en) 2021-07-14
BR112021004141A2 (en) 2021-05-25
AU2019336214A1 (en) 2021-04-29

Similar Documents

Publication Publication Date Title
ZA202004494B (en) Anti-tmprss2 antibodies and antigen-binding fragments
IL269593A (en) Anti-ilt4 antibodies and antigen-binding fragments
IL262092A (en) Humanized anti-pacap antibodies and uses thereof
IL263481A (en) Anti-c5 antibodies and uses thereof
IL269122A (en) Anti-c5 antibodies and uses thereof
IL281272A (en) Humanized anti-c5 antibodies and uses thereof
IL283812B (en) Humanized anti-human-pd-1 antibody
ZA201701920B (en) Anti-human il-17 monoclonal antibodies and use thereof
IL275734B (en) Anti-pd-l1 antibodies and uses thereof
IL282756A (en) Humanized anti-sirpα antibodies
RS63580B1 (en) Humanized anti clever-1 antibodies and their use
IL275264A (en) Anti-c5 antibody combinations and uses thereof
SG11202103095RA (en) Anti-human vsig4 antibodies and uses thereof
IL281608A (en) Anti-human cd45rc antibodies and uses thereof
ZA202004784B (en) Humanized and de-immunized antibodies
ZA202101668B (en) Humanized anti-vegfr2 single-chain antibody and use thereof
IL277296A (en) Anti-pfrh5 antibodies and antigen-binding fragments thereof
GB201911211D0 (en) Monoclonal antibodies against ambra-1
GB201918103D0 (en) Epitopes and antibodies
GB201918104D0 (en) Epitopes and antibodies